The multivalent effect of carbohydrates (glycoclusters) has been explored to study important biological targets and processes involving Trypanosoma cruzi (T. cruzi) infection. Likewise, CuAAC cycloaddition reactions (click chemistry) have been applied as useful strategy in the discovery of bioactive molecules. Hence, we describe the synthesis of 1,2,3-triazole-based tetravalent homoglycoclusters (1-3) and heteroglycoclusters (4 and 5) of d-galactopyranose (C-1 and C-6 positions) and sialic acid (C-2 position) to assess their potential to inhibit T. cruzi cell invasion and also its cell surface trans-sialidase (TcTS). The target compounds were synthesised in good yields (52-75 %) via click chemistry by coupling azidosugars galactopyranose and sialic acid with alkynylated pentaerythritol or tris(hydroxymethyl)-aminomethane (TRIS) scaffolds. T. cruzi cell invasion inhibition assays showed expressive low parasite infection index values (5.3-6.8) for most compounds. However, most glycoclusters proved to be weak TcTS inhibitors at 1 mM (<17 %), except the tetravalent sialic acid 3 (99 % at 1 mM, IC 50 450 μM). Therefore, we assume that T. cruzi cell invasion blockage is not due to TcTS inhibition by itself, but rather by other mechanisms involved in this process. In addition, all glycoclusters were not cytotoxic and had significant trypanocidal activity upon parasite survival of amastigote forms.
Introduction
Chagas disease (American Trypanosomiasis) is a parasitic illness caused by the protozoan Trypanosoma cruzi (T. cruzi) and is considered one of the most significant neglected diseases. Though limited to Latin America in the past, the disease is currently spread to other continents due mainly to population mobility and approximately seven million people are infected worldwide [1, 2] . Amongst the different ways of transmission, the most common is by contact with faeces of infected triatomine bugs. The highly infectious trypomastigote form circulates in the bloodstream and invades cells to escape from the host immune system and to Article note: A collection of invited papers based on presentations at the 29 th International Carbohydrate Symposium (ICS-29), held in the University of Lisbon, Portugal, 14-19 July 2018. differentiate in amastigote form until cell disruption and subsequent spread of the parasite [3, 4] . The current medical treatment relies on the two old nitro-heterocyclic drugs benznidazole and nifurtimox, which present severe side effects and poor efficacy in chronic stages. In this sense, the treatment remains unsatisfactory and consequently the need of new drugs demands urgent action [4, 5] .
T. cruzi expresses a unique cell surface trans-sialidase enzyme (TcTS) that catalyzes the transfer of sialic acids from host glycoconjugates to terminal β-galactopyranosyl residues of mucin-like glycoproteins present on the parasite surface. As a result of this trans-sialylation, the parasite can be recognized by host cells and becomes protected against the host immune responses. In fact, TcTS is involved in crucial interactions between host cells and parasite that regulate cellular invasion processes and infection. Moreover, the evidence that TcTS high level in the bloodstream has a great impact on the parasite persistence and pathogenesis during the acute phase of the disease [6] makes this enzyme an important drug target to be explored [7] [8] [9] . Additionally, there are no potent reversible inhibitors at nanomolar range toward this enzyme to date [10, 11] .
It is well known that copper-catalyzed azide-alkyne cycloaddition -CuAAC ('click chemistry') [12, 13] and multivalency (glycoclusters, oligomers, dendrimers, etc.) [14, 15] are relevant concepts in the discovery of bioactive molecules and have been extensively applied to a wide range of targets. Despite considerable structural similarity to microbial and viral sialidases (neuraminidases), TcTS is primarily insensitive to the classical inhibitors used as anti-flu drugs (oseltamivir and zanamivir) and the use of multivalent approach has not been extensively applied to TcTS, such as sialylated conjugates installed on dendrimers [16, 17] , calixarene [18] , fullerene [19] and dendrimeric carbosilane [15] scaffolds that showed potent inhibitory activity against human influenza virus and other enzymes.
Based on the extensive study of T. cruzi surface trans-sialidase and mucin glycoproteins, we have previously reported that linear and cyclic pseudo-galactooligosaccharides, [20] and larger macrocycles [21] were recognized as acceptor substrate by TcTS. Furthermore, the ability of these TcTS ligands to block T. cruzi invasion to macrophages encourage us to continue these studies focusing on a multivalent approach using β-galactopyranoside and sialic acid residues as natural substrates for enhancing the ligand recognition by parasite membrane proteins and prevent the cellular invasion process. Thus, multivalent non-hydrolysable 1,2,3-triazole-linked sugars could provide higher local concentration of galactose, sialic acid or both ligands at the acceptor and donor TcTS subsites during the trans-sialylation reaction acting with high affinity through specific binding.
Hence, we envisaged the synthesis of tetravalent 1,2,3-triazole-linked d-galactopyranose at C-1 (1) and C-6 (2) positions and sialic acid at C-2 position (3) homoglycoclusters from pentaerythritol ( Fig. 1) as well as heteroglycoclusters bearing three galactopyranose units and one sialic acid attached to a bifunctional scaffold (4 and 5) in order to evaluated their potential to block T. cruzi cell invasion. Moreover, TcTS inhibitory activity and parasite survival (trypanocidal activity against T. cruzi trypomastigote and amastigote forms) were also assessed.
Results and discussion

Synthesis of tetravalent homoglycoclusters
The conjugation of tetravalent cluster glycosides 1-3 onto a multifunctional scaffold (Scheme 1) required the previous preparation of the pentaerythritol-derived tetra-alkyne 6 and peracetylated sugar azides 7-9 as precursors (Scheme 2).
The tetravalent alkyne 6 was synthesised in one step from commercially available pentaerythritol and propargyl bromide with KOH in anhydrous DMF in moderate yield (38 %), as expected from literature (Scheme 2a) [16] . Galactose derivatives bearing an azide group at either C-1 or C-6 positions and sialic acid azide (functionalized at C-2) were prepared according to reported procedures (Scheme 2b-d) [22, 10, 23] . Briefly, 2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl azide 7 was obtained in two steps from peracetylated d-galactose in 90 % overall yield [22] . The synthesis of methyl 2,3,4-tri-O-acetyl-6-azido-6-deoxy-β-d-galactopyranoside 8 [10] was carried out with initial formation of the corresponding 6-tosylate intermediate (methyl 2,3,4-tri-Oacetyl-6-tosyl-6-deoxy-β-d-galactopyranoside) in one-pot tosylation/acetylation reaction (47 % overall yield) followed by displacement of tosyl group with NaN 3 in DMF (90 % yield). Lastly, α-sialic acid azide 9 was obtained in 63 % yield in one step from the corresponding β-chloride and NaN 3 using a phase-transfer catalysis method described by Tropper and co-workers (1991) [23] .
A controlled number of bioactive ligands was achieved by coupling propargylated scaffold 6 with azidosugars 7-9 via click chemistry to give protected glycoclusters 10-12 in good yields (52-72 %) and selectivity (Scheme 1). The reactions were conducted on a small scale (0.025 mM of alkyne) with 10 mol% excess of azidosugar per alkyne functional group and with copper sulfate/sodium ascorbate for in situ generation of the Cu(I) catalyst [10] . The coupling reactions of compounds 7 and 8 with building block 6 were conducted in a sealed tube under microwave-assisted conditions at 80 °C in DMF (0.1 mL). Despite some unsuccessful attempts to prepare glycocluster 12 using this same condition or the synthetic protocol described by Weïwer and co-workers (2009), [16] the desired compound was only obtained under conventional heating at 60 °C in DMF (12 h). The structures of peracetylated 1,2,3-triazole-glycoclusters (10-12, Scheme 1) were confirmed by 1 H and 13 C NMR spectroscopy and HRMS-ESI analyses. 1 H NMR spectra showed complete functionalization of alkyne 6 in all four positions as the four triazole hydrogens can be clearly observed in the range δ 7.75-8.16 ppm (see Supplementary material).
Subsequently, O-deacetylation with NaOMe (1 M in methanol) afforded the fully deprotected glycoclusters 1 and 2 in near quantitative yield. Treatment of dendrimer 12 with NaOMe (1 M in methanol) was followed by saponification of the methyl ester groups using KOH 0. 
Synthesis of heteroglycoclusters
The synthesis of two new tetravalent heteroglycoclusters (4 and 5) was conducted on the bifunctional dendrimer scaffold 13 using the same click chemistry approach to enable the arrangement of two non-identical ligands in a 3:1 ratio [24] (e.g. three galactopyranose units and one sialic acid moiety), as outlined in Scheme 3. The dendrimer scaffold 13 [25] was synthesised in two steps from commercially available tris(hydroxymethyl)aminomethane (TRIS) in 30 % yield and the trivalent clusters clicked at galactopyranose C-1 (14) or C-6 (15) using azidosugars 7 and 8, (respectively) under similar reaction conditions as for galactoclusters 10 and 11. The Boc-cleavage of compounds 14 and 15 in acidic condition (TFA) afforded intermediates 16 and 17, which were subsequently converted to the corresponding azido dendrimers 18 and 19 in good yields (64 % and 61 %, respectively) by diazo-transfer reaction with imidazole-1-sulfonyl azide hydrogen sulfate [26] 
Biological assays
Inhibition of T. cruzi cell invasion
Inhibition of fibroblast cells invasion by T. cruzi (Y strain) was performed by treating the cells (LLCMK2), previously adhered in circular coverslips, with compounds 1-5 (25-250 μM) followed by addition of trypomastigote forms (5 parasites/cell). The cultures were incubated for 18 h and the coverslips were fixed and stained to assess the cell infection levels [27, 28] . According to the results (Fig. 2) , the glycoclusters 1-4 were able to significantly reduce the percentage of infected fibroblasts at 25 μM (Fig. 2c) . The effect of the treatment caused a decreased value of cell infection, a 24 % reduction on average when compared to non-treated cells (43 %). Regarding the number of amastigotes within the cells (Fig. 2b) , homo-and heteroglycoclusters 1-4 showed also reduction (0.20 parasite/cell on average) compared to the control (0.56 parasite/cell). Accordingly, the infection index values (percentage of infected cells multiplied by average number of amastigotes per cell) for compounds 1-4 were considerably low ( Fig. 2c) , ranging from 5.3 to 6.8 vs. 28.3 for the control. Despite the structural similarity between the heteroglycoclusters 4 and 5, the low inhibition activity of 5 may be explained by the different spatial arrangement of the galactose unit that could compromise important interactions between their exposed hydroxyl groups and molecules found on cell surface. Although it is not possible to stablish any study of structure-activity relationship, since both homo-and heteroglycoclusters (except 5) equally reduced the parasite infection, it is clear that most of them proved to efficiently inhibit cell invasion by T. cruzi. This promising result encouraged us to explore their possible trypanocidal effect upon trypomastigote and amastigote forms as well as inhibitory activity towards TcTS.
Trypanocidal activity and cytotoxicity
Trypomastigote forms of T. cruzi (Y strain) were treated with compounds 1-5 in concentrations ranging from 62.5 to 250 μM in order to investigate their possible trypanocidal activity using resazurin method [29] and having the drug benznidazole (BZD) as positive control. Based on the results (Fig. 3a) , none of the compounds showed significant trypanocidal effect at 250 μM, which is 10-fold higher than the concentration used in cell invasion inhibition assay. Therefore, the lack of trypanocidal activity and T. cruzi cell invasion inhibition are not correlated. In order to evaluate the cytotoxicity for mammalian cells by MTT method, [29] fibroblasts (LLCMK2) were seeded in 96-wells plates and exposed to different concentrations of compounds 1-5 62.5-250 μM. The results at 250 μM (Fig. 3b) indicated that the glycoclusters were not cytotoxic for LLCKM2 cells at the concentrations tested.
Trypanocidal activity for intracellular amastigotes
The trypanocidal activity of glycoclusters 1-5 for intracellular amastigote forms of T. cruzi was also evaluated by treating infected fibroblasts with the compounds in different concentrations (25-200 μM) for 48 h. Benznidazole was used as control at a concentration of 30 μM. Based on the results at 25 μM (Fig. 4) , the lowest effective concentration tested in cell invasion inhibition assay, all glycoclusters reduced the percentage of infected cells (Fig. 4a) , the average number of amastigotes per cell (Fig. 4b) and, consequently, of infection index (Fig. 4c) , when compared to untreated cells. Although compound 5 showed the weakest trypanocidal activity, these results indicate that both homo-and heteroglycoclusters were more effective against intracellular parasites found in mammalian cells than extracellular forms.
Inhibition of T. cruzi trans-sialidase (TcTS)
The inhibitory activities of the multivalent glycoclusters 1-5 toward T. cruzi trans-sialidase were evaluated by continuous fluorimetric assay, which is based on the residual hydrolase activity of TcTS that releases 4-methylumbelliferone (Mu) for detection upon cleavage of the substrate 2-(4-methylumbelliferyl)-α-d-Nacetylneuraminic acid (MuNANA) [30] . Compounds 1-5 were initially assessed at 1.0 mM in the presence of the substrate MuNANA at 0.1 mM and pyridoxal phosphate was used as positive control [31] .
According to the results (Fig. 5) , only the tetravalent sialic acid glycocluster 3 showed high inhibitory activity (99 %, IC 50 450 μM) against TcTS, whereas weak or no inhibitory activity was observed for the other glycoclusters (0-17 %). Although compounds 1, 2, 4 and 5 display a β-galactose unit, which is in principle able to naturally bind to TcTS active site in the acceptor substrate pocket, the lack of inhibition may be explained by no relevant impact of these compounds upon hydrolysis, even considering their potential to bind to the catalytic site. On the other hand, the outstanding inhibitory activity of the sialic acid-based derivative 3 strongly suggests a possible competition with MuNANA for the donor substrate pocket, thus affecting the enzymatic reaction outcome. More importantly and also unexpected, these results seem not to be associated with the expressive low parasite infection index values of compounds 1-4, since TcTS is well-known to be involved in key interactions between host cells and parasite that control cellular invasion processes. In this context, we may assume that T. cruzi cell invasion blockage observed for 1-4 is not a consequence of TcTS inhibition, rather other mechanisms should be involved in this process.
Conclusions
We have successfully designed and synthesised 1,2,3-triazole-based tetravalent homoglycoclusters (1-3) and heteroglycoclusters (4 and 5) of d-galactopyranose and sialic acid via CuAAC cycloaddition reactions in good yields (52-75 %) after few steps. Remarkably, most glycoclusters exhibited expressive low parasite infection index values (5.3-6.8), thus proving to be highly potent inhibitors of T. cruzi cell invasion. On the other hand, most glycoclusters showed only weak TcTS inhibition activity at 1 mM (<17 %), except the tetravalent sialic acid 3 (99 %, IC 50 450 μM). Therefore, we may assume that T. cruzi cell invasion blockage is not due to TcTS inhibition by itself, but rather by other mechanisms involved in this process. Additionally, all glycoclusters were assessed for cytotoxicity and trypanocidal activity in fibroblasts, however none of them were neither cytotoxic nor had a significant inhibitory activity upon T. cruzi trypomastigote forms. Therefore, glycoclusters 1-4 can be considered promising trypanocidal compounds taking into account their great ability to block cell invasion by T. cruzi and drastically reduce the intracellular parasite infection (amastigote forms). Further studies are underway to better understand their mechanism of action. 
Experimental General
All chemicals were purchased as reagent grade and used without further purification. Reactions were monitored by thin layer chromatography (TLC) on 0.25 nm precoated silica gel plates (Whatman, AL SIL G/UV, aluminium backing) with the indicated eluents. Compounds were visualized under UV light (254 nm) and/or dipping in ethanol-sulfuric acid (95:5, v/v), followed by heating the plate for a few minutes. Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Avance DRX 300 (300 MHz), DPX 400 (400 MHz) or DPX 500 (500 MHz) spectrometers. Chemical shifts (δ) are given in parts per million downfield from tetramethylsilane (TMS). Assignments were made with the aid of HMQC and COSY experiments. Accurate mass electrospray ionization mass spectra (HRMS-ESI) were obtained using positive or negative ionization modes on a Bruker Daltonics MicroOTOF II ESI-TOF mass spectrometer. 
2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl azide 7
Peracetylated galactose (0.78 g, 2.56 mmol) was dissolved in a HBr solution (3.4 mL, 33 wt. % in acetic acid) and the mixture was stirred at room temperature for 3 h. The resulting solution was then diluted in DCM (22 mL) and further washed with satd NaHCO 3 solution and brine. The organic layer was concentrated under reduced pressure (5 mL) then TBAHS (0.18 g, 0.55 mmol), NaN 3 (0.709 g, 10.9 mmol) and aqueous NaHCO 3 (4.3 mL). The mixture was stirred vigorously at room temperature for 18 h and then extracted with ethyl acetate (20 mL × 2). The organic layer was then collected, washed successively with satd NaHCO 3 solution, brine and water, dried over anhydrous MgSO 4 
Methyl 2,3,4-tri-O-acetyl-6-deoxy-6-azido-β-d-galactopyranoside 8
Under argon atmosphere, methyl β-d-glucopyranoside (0.50 g, 2.67 mmol) was dissolved in dry pyridine (6 mL) and cooled (0 °C). Tosyl chloride (1.41 g, 7.5 mmol) was slowly added and the reaction mixture was stirred for 10 h at room temperature. Acetic anhydride (1.2 mL) was then added and the mixture stirred for 12 h. The final suspension was concentrated by co-evaporation with toluene, diluted with DCM, and the organic layer was washed with 1 M HCl, satd NaHCO 3 solution, dried over anhydrous MgSO 4 and concentrated under reduce pressure. The crude product was purified by flash chromatography [EtOAc/Tol, 10-30 %] to afford the 6-tosyl intermediate (0.59 g, 1.25 mmol, 47 %). A suspension of methyl-2,3,4-tri-O-acetyl-6-O-ptoulenesulfonyl-β-d-galactopyranoside (0.39 g, 0.82 mmol) in DMF (10 mL) containing sodium azide (0.82 g, 12.5 mmol) was heated at 100 °C for approx. 24 h. The solution was allowed to cool, diluted with water and extracted with DCM. The organic layer was washed with water, satd NaHCO 3 solution and water, dried over anhydrous MgSO 4 
Methyl [5-Acetamido-3,5-dideoxy-4,7,8,9-tetra-O-acetyl-2-azido-d-glycero-α-d-galacto-non-2-ulopyranoside]onate 9
Methyl [5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-acetyl-2-chloro-d-glycero-β-d-galacto-non-2-ulopyranoside] onate (0.15 g, 0.3 mmol), tetrabutylammonium hydrogen sulfate (0.10 g, 0.3 mmol) and sodium azide (0.10 g, 1.5 mmol) were dissolved in a mixture of DCM/satd NaHCO 3 solution 1:1 (100 mL) and stirred vigorously for 3 h at room temperature. Dichloromethane was then added and the two phases were separated. The organic layer was washed with satd NaHCO 3 solution, dried with sodium sulfate and filtered. Evaporation of the solvent under reduced pressure afforded compound 9 as a white solid (0.095 g, 0.19 mmol, 63 % 
Glycocluster 10
Alkyne 6 (0.007 g, 0.025 mmol) was dissolved in DMF (0.1 mL in a microwave flask). After dissolution, azide 7 (1.1 mol eq. for each alkyne termination), sodium ascorbate (0.1 mol eq.) and CuSO 4 (0.05 mol eq.) were added and the tube was sealed. The mixture reaction was stirred and heated for 15 min. at 80 °C (3 ×) in the microwave and concentrated under reduced pressure (residual DMF co-evaporated with toluene). The crude product was purified by flash chromatography [EtOAc/Hex, 0-100 %] to afford peracetylated glycocluster 10 (0.03 g, 0.018 mmol, 75 %). 
Glycocluster 11
The method described above for compound 10 was followed to obtain galactose glycocluster 11 (using azide 8 instead of azide 7), a white foam (0.023 g, 0.014 mmol, 58 % 
Glycocluster 12
Alkyne 6 (0.007 g, 0.025 mmol), azide 9 (1.1 mol eq. for each alkyne termination), CuSO 4 (10 % w/v) and sodium ascorbate (0.01 g, 0.05 mmol) were dissolved in DMF (2 mL) and the mixture reaction was stirred at 60 °C for 12 h. The final suspension was concentrated by co-evaporation with toluene and the crude product was purified by flash chromatography [AcOEt/n-hexane 0-100 %, followed by DCM/ 
tert-butyl (1,3-bis(prop-2-yn-1-yloxy)-2-((prop-2-yn-1-yloxy)methyl)propan-2-yl)carbamate 13
To a suspension of tris(hydroxymethyl)aminomethane (2.0 g, 16.5 mmol) in t-BuOH (20 mL), a solution of ditert-butyl dicarbonate (3.60 g, 16.4 mmol) in a 1:1 mixture of MeOH:t-BuOH (32 mL) was added slowly and the reaction mixture was stirred at room temperature for 22 h. Then, the solvents were evaporated under reduced pressure to give a crude white residue which was recrystallized from cold ethyl acetate. Vacuum filtration of the white solid subsequently afforded pure tert-butyl (1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate in 64 % yield. To a solution of the protected tris(hydroxymethyl)aminomethane (2.32 g, 10.5 mmol) in dry DMF, propargyl bromide (80 wt. % in toluene) (5.7 mL, 364.3 mmol) was added and the reaction mixture was stirred at 0 °C for 10 min. It was followed by the addition of finely powdered KOH (3.56 g, 63.4 mmol) in small portions. The reaction mixture was then stirred at room temperature for 40 h. To the resulting brown coloured mixture, ethyl acetate was added, and the reaction mixture stirred for another 10 min. Further, the entire reaction mixture was washed successively with water (2 × 10 mL) and brine (10 mL). The organic layer was collected, dried over anhydrous MgSO 4 
Glycocluster 14
Alkyne 13 (0.15 mmol) was dissolved in DMF (0.1 mL in a microwave flask). After dissolution, azide 7 (1.1 equiv. for each alkyne termination), sodium ascorbate (0.1 equiv.) and CuSO 4 (0.03 mol eq.) were added and the tube was sealed. The mixture was stirred and heated for 15 min. at 80 °C (3 ×) in the microwave and concentrated under reduced pressure (residual DMF co-evaporated with toluene). The crude product was purified by flash chromatography (EtOAc/Hex, 0-100 %) to afford protected glycocluster 14 (0.186 g, 0.12 mmol, 84 %). 
Glycocluster 15
The method described for compound 14 was followed to obtain the trivalent glycocluster 15 (using azide 8 instead of azide 7) (0.189 g, 0.135 mmol, 89 %). 
Glycocluster 18
To a solution of compound 14 (0.16 g, 0.11 mmol) in DCM (1 mL) at 0 °C, 1 mL of trifluoroacetic acid was added dropwise. The reaction mixture was then stirred at room temperature for 2 h till the TLC showed complete consumption of the starting material to a slower moving spot. The solvents were evaporated and successively co-evaporated with toluene and methanol. The syrupy compound 16, obtained without purification, was dissolved in methanol (4 mL) followed by the addition of catalytic CuSO 4 , NaHCO 3 (16.5 mg, 0.23 mmol) and the diazotransfer reagent imidazole-1-sulfonyl azide (hydrogen sulfate) (1.6 mol eq. 0.18 mmol, 47.5 mg). The pH was adjusted to 8-9 with NaHCO 3 solution. The resulting mixture was then stirred at room temperature for 16 h. The solvents were evaporated, and the residue was dissolved in DCM, washed successively with water and HCl solution (3 %). The organic layer was collected, dried over anhydrous MgSO 4 and filtered. The solvents were then evaporated under reduced pressure to afford compound 18 in 64 % yield (two steps) (0.09 g, 0.08 mmol, 64 %). 
Glycocluster 19
The method described above for compound 18 was followed to obtain glucose glycocluster 19 (using glycocluster 15 as starting material) (0.156 g, 0.12 mmol, 80 %, two steps). 
Glycocluster 21
Azide-functionalized dendrimer 18 (0.065 g, 0.05 mmol) was dissolved in DMF (0. 
Deprotection reactions
Condition 1
The peracetylated galactose glycoclusters were fully characterized prior the deprotection. The acetate was dissolved in methanol (1.0 mL) and sodium methoxide (1.0 M in methanol) was added until pH 9.0 was achieved. After stirring at room temperature for 1.5 h, the mixture was neutralized with ion exchange resin DOWEX 
Biological assays
Inhibition of T. cruzi cell invasion
Inhibition of fibroblast cells invasion by T. cruzi was carried out by treating with 200-25 μM of compounds 1-5 previously adhered LLCMK2 fibroblasts in circular coverslips (3 × 10 5 cells per well in 500 μL of RPMI 1640 supplemented with penicillin, streptomycin, L-glutamine, and 10 % FBS) and, after 30 min, adding 1.5 × 10 6 trypomastigote forms of T. cruzi (in a proportion of five parasites for each fibroblast). The cultures were incubated for 18 h at 37 °C and 5 % CO 2 , then the coverslips were fixed and stained with fast panoptic dye (Laborclin, Brazil). The coverslips were mounted to glass slides with Entellan (Merck Millipore, USA) and examined under an optical microscope. Each concentration was examined in triplicate, considering 100 fibroblasts per coverslip. The level of parasitic cell invasion was determined using three parameters: i) percentage of infected cells; ii) mean number of T. cruzi amastigotes by cell; iii) infection index that was determined by multiplying the percentage of infected cells times by the mean number of parasites per cell, as described previously [27, 28] .
Citotoxicity assay
LLCMK2 fibroblasts were seeded in 96-wells plates (1 × 10 4 cells in 200 μL per well) in RPMI 1640 supplemented with penicillin, streptomycin, L -glutamine, and 10 % FBS. After adhering overnight at 37 °C and 5 % CO 2 , the medium was replaced by fresh RPMI medium with different concentrations of compounds 1-5 (1000-62.5 μM) in triplicate and cultured at 37 °C and 5 % CO 2 for 24 h. Cells treated with 30 μM oxygen peroxide were used as death control. Then, 20 μL of a 5 mg/mL of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT, Sigma-Aldrich, USA) were added to each well and incubated for 4 h at 37 °C and 5 % CO 2. The medium was discarded and 200 μL of DMSO was added to each well to dissolve formazan crystals, and then the plate was read at 570 nm (UV mini 1240, Shimadzu). Cells viability was assessed from the OD in 570 nm and comparing with untreated cells [29] .
Trypanocidal assay
Culture derived tripomastigote forms of T. cruzi (Y strain) were seeded in 96-wells plates (1 × 10 6 cells in 200 μL per well) in RPMI 1640 supplemented with penicillin, streptomycin, L -glutamine, and 10 % FBS containing different concentrations of the compounds 1-5 (ranging from 1000 to 62.5 mM) and incubated at 37 °C and 5 % CO 2 for 24 h. Parasites treated with 30 μM benznidazole (BZD) were used as death control. Then, 5 μL of a 1 mg/mL solution of resazurin (SigmaAldrich, USA) were added to each well and, 4 h after 37 °C and 5 % CO 2 incubation the plates were read at 570 and 600 nm (UV mini 1240, Shimadzu). The parasites viability was assessed subtracting the OD in 600 nm from the OD in 570 nm and comparing with untreated cells [29] .
Trypanocidal activity in intracellular amastigotes
Fibroblasts (LLCMK2) were plated on circular coverslips (3 × 10 5 cells per well in 500 μL) in 24-well plates, and incubated in RPMI medium at 37 °C and 5 % CO 2 for overnight adhesion, then infected with 1.5 × 10 6 trypomastigote forms of T. cruzi (Y strain) per well, in a ratio of 5:1 (parasites: cell) and incubated in RPMI medium for 24 h at 37 °C and 5 % CO 2 for infection. The wells were then washed and infected cells were treated with 200-25 μM solutions of each test compound, diluted in RPMI medium, for 48 h at 37 °C and 5 % CO 2 . Infection controls (IC) received only RPMI medium, and the death control wells were treated with benznidazole (BZD) at 30 μM. At the end of the treatment the coverslips were washed, stained with panoptic dye (Laborclin) and mounted to glass slides with Entellan (Merck Millipore, USA) for counting the number of infected cells and the number of amastigote forms inside the fibroblasts under an optical microscope. Each concentration was tested in triplicate, and a total of 100 macrophages were counted per cover slip, considering the same parameters used for cell invasion assay, described above.
Inhibition of T. cruzi trans-sialidase (TcTS)
trans-Sialidase used in this study was a His-tagged 70 kDa recombinant material truncated to remove C-terminal repeats but retaining the catalytic N-terminal domain of the enzyme [32] . Inhibition was assessed using the continuous fluorimetric assay described by Douglas and co-workers [30] . Briefly, the assay was performed in triplicate in 96-well plates containing phosphate buffer solution at pH 7 (25 μL), recombinant enzyme solution (25 μL) and inhibitor solution (25 μL of 4.0 mM solution). This mixture was incubated for 10 min. at 26 °C followed by addition of MuNANA (25 μL of a 0.4 mM solution affording an assay concentration of 0.1 mM). The fluorescent product released was measured over 5 min., with excitation and emission wavelengths of 360 and 460 nm, respectively, and the data were analyzed with GraphPad Prism software version 4.0 (San Diego, CA, USA). Inhibition percentages were calculated according to the equation: % I = 100 [1 (V i /V 0 )], where V i is the velocity in the presence of inhibitor and V 0 is the velocity in absence of inhibitor.
